Short bowel syndrome
Short bowel syndrome is an extremely rare, chronic, leading to disability and potentially life-threatening condition in which a person cannot absorb enough nutrients from food for survival due to loss of intestinal absorption capacity. This condition develops as a result of extensive resection of the intestine, the causes of which can be injuries, various bowel diseases (for example, Crohn's disease), vascular complications; or due to congenital malformations.
Content |
Short bowel syndrome with intestinal failure
Short bowel syndrome with intestinal insufficiency (CCS-CH) - a decrease in the functionality of the small intestine as a result of resection or congenital defects, leading to chronic intestinal insufficiency and impaired adequate growth and development of the patient.
According to 2014 world data, the prevalence of short bowel syndrome with intestinal insufficiency (CCS-CH) varies from 1 to 5 cases per 1 million [1] Lethality in short bowel syndrome ranges from 11 to 37.5%.
Patients with CCM-K need to maintain life through parenteral nutrition (PP) and infusion therapy (IT) throughout their lives. Despite the fact that PP/IT saves the patient, it cannot fully replace enteral nutrition, and dependence on such therapy can lead to the development of serious complications and diseases. This is a high-cost long-term treatment that limits the patient in moving and conducting a full-fledged lifestyle. Manifestations of CCS-CN and complete dependence on parenteral nutrition can lead to the development of serious complications, such as infections and sepsis, thrombosis and liver damage, as well as a significant deterioration in the quality of life.
People with short bowel syndrome suffer from a variety of debilitating symptoms, including dehydration, diarrhea, fatigue, and weakness. A study by British gastroenterologist scientists covering a 30-year history of sightings of CCM-CN patients notes high lethality among patients on lifetime PP/IT with reduced survival rates over time.
Therapy
2021
A mobile application for patients with short bowel syndrome has appeared in Russia
On September 17, 2021, Takeda announced the development of a mobile application myPNtracker to help the doctor and patient in assessing the health of patients with short bowel syndrome (CCS). More details here.
Russia registered the world's first drug for the treatment of CCS-KN
In July 2021, it was announced that Takeda Russia received a registration certificate for Gattestiva (international generic name - teduglutide), the world's first drug approved for the treatment of patients with short bowel syndrome with intestinal insufficiency (CCS-KN) aged 1 year and older.
Notes
- ↑ people Kelly DG, Tappenden KA, Winkler MF. Short bowel syndrome: Highlights of patient management, quality of life, and survival. JPEN J Parenter Enteral Nutr 2014;38(4):427–37.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |